Anaplastic thyroid cancer

ICD-10 C73 · ICD-11 2D10.3

Treatment of Anaplastic Thyroid Cancer Stage IVC with High PD-L1 Expression

Clinical Scenario

Stage IVC · High PD-L1 Expression

This protocol addresses patients with anaplastic thyroid cancer presenting at stage IVC and demonstrating high PD-L1 expression in the thyroid tumor. The biomarker profile shapes the choice of first-line systemic therapy.

Approach — Partial Overview

In this setting, therapy directed at immune checkpoint pathways (targeting PD-L1 and PD-1) is a recognised first-line option. The complete regimen, sequencing, and clinical-trial context are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1089/thy.2020.0944

In IVC ATC patients with high PD-L1 expression, checkpoint (PD-L1, PD1) inhibitors can be considered first-line therapy in the absence of other targetable alterations or as later line therapy, preferably in the context of a clinical trial.

View source ↗